Trump Expected to Fire FDA Head Amid Agency Turbulence
Published on 5/8/2026

AI Summary
Marty Makary is reported to be the latest high-profile health official facing termination, as political dynamics shift within the Trump administration. His departure continues a trend of leadership changes affecting key health agencies. This could impact the Food and Drug Administration (FDA) as it navigates ongoing public health challenges. Market reactions to such changes in leadership at the FDA can lead to volatility in healthcare stocks.
Related News

Earnings
MannKind Corporation (MNKD) Price Target Raised to $11 by Wells Fargo
Jun 13

MedTech
Medtronic (MDT) Gains FDA Approval for New Robotic Surgery Platform
Jun 8

Health
GLP-1 Drugs: New Weight-Loss Therapies Under Development
Jun 6

Regulation
Alvotech (ALVO) Receives FDA Form 483 from June 2026 Inspection
Jun 6